National Multiple Sclerosis Society (NMSS)

eSupport Health was established in November 2019, as a Delaware Public Benefit Corporation, to provide practical, actionable solutions that improve mental health for people living with MS and other chronic conditions. The company currently offers professional support groups for (1) people living with MS, (2) people newly diagnosed with MS, and (3) loved ones and family members of people living with MS. Groups meet weekly via secure online video and are moderated by experienced coaches who are licensed therapists with MS expertise. The first month is free of charge. eSupport Health also offers free monthly workshops, open to everyone who registers.

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient’s own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson’s disease, Huntington’s disease, and autism spectrum disorder. The company has a partnership with Catalent for the manufacture of NurOwn, an autologous cellular therapy. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.

Clene Nanomedicine is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases. The company has created a unique nanotechnology drug platform that facilitates the discovery and commercialization of a new class of orally-administered neurotherapeutic drugs. Utilizing an electro-crystal-chemistry approach, Clene produces concentrated, stable nanocrystal suspensions that are designed to enhance therapeutic efficacy. In addition to its primary focus on neurodegenerative diseases, Clene also operates in the dietary supplements sector, highlighting its commitment to advancing health solutions through cutting-edge technology.

Longevity Biotech, Inc. is a biopharmaceutical company based in Philadelphia, Pennsylvania, founded in 2010. The company specializes in the development of therapeutic drug candidates using innovative artificial protein technology. Its signature product, Hybridtide, is a peptide scaffold designed to enhance the stability and efficacy of therapeutic peptides. Longevity Biotech's pipeline includes several promising candidates, such as LBT-3627, a neuroprotective agent aimed at treating disorders like Parkinson's disease; LBT-6030, a dual agonist targeting glucagon; and LBT-5001, a fusion inhibitor. Additionally, the company is conducting clinical studies to identify immune and inflammatory markers that may aid in the diagnosis of Parkinson's disease. With a focus on creating biologic-like molecules that are resistant to digestive breakdown, Longevity Biotech is positioned to contribute significantly to advancements in pharmaceutical therapeutics.